Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice
Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice
复制标题
DOI：
10.1186/1757-4749-3-16
复制
发表时间：
2011-10-20
期刊：
影响因子：
4.2
通讯作者：
Keller, David
中科院分区：
文献类型：
--
作者：
Fitzpatrick, Leo R.;Small, Jeffrey S.;Keller, David
背景：益生菌在艰难梭菌（C. difficicle）诱导的结肠炎。芽孢形成益生菌菌株凝结芽孢杆菌GBI-30，6086（BC 30）已在体外显示出抗炎和免疫调节作用。我们的目标是确定BC 30是否改善了C。艰难梭菌诱导的小鼠结肠炎。从研究第0天开始，雌性C57 BL/6小鼠经口灌胃给予溶媒（生理盐水）或BC 30（2 x 10（9）CFU/天），持续15天。小鼠在C.艰难梭菌组接受抗生素混合物（研究第5 - 8天在饮用水中）和克林霉素（10 mg/kg，i. p.，在研究第10天）。梭在第11天通过管饲法给予10（4）CFU的艰难梭菌菌株VPI 10463以诱导结肠炎。结果：所有用BC 30处理的小鼠在研究第13天存活，而用载体处理的两只小鼠没有存活。在第12天，在BC 30/C中发现具有正常粪便的小鼠百分比（66.7%）存在显著差异（p = 0.0002）。艰难梭菌组，与溶媒/C.难治组（13.0%）。在研究第16天，23.8%的用BC 30处理的小鼠具有正常粪便，而该值在用媒介物处理的情况下为0%（p值= 0.0187）。在这一天，粪便硬度评分为BC 30/C。艰难梭菌组（1.1 +/-0.2）显著低于（p < 0.05）载体/C。艰难梭菌队列（1.9 ± 0.2）。BC 30适度减弱了C.艰难感染结肠MIP-2趋化因子含量（μ g/2cm结肠）为：10.2 ± 0.5（载体/无C.艰难梭菌）、24.6 +/- 9.5（媒介物/C.艰难梭菌）和16.3 +/-4.3（BC 30/C.结论：益生菌BC 30可改善C.艰难梭菌诱导的小鼠结肠炎。BC 30延长了C. difficile感染的小鼠。特别地，这种益生菌在这种感染性结肠炎模型中改善了小鼠的粪便稠度。
Background: Probiotics have beneficial effects in rodent models of Clostridium difficile (C. diffiicle)-induced colitis. The spore forming probiotic strain Bacillus Coagulans GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and immune-modulating effects in vitro. Our goal was to determine if BC30 improved C. difficile-induced colitis in mice. Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 x 10(9) CFU per day). Mice in the C. difficile groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The C. difficile strain VPI 10463 was given by gavage at 10(4) CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses.Results: All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in the BC30/C. difficile group, as compared to the vehicle/C. diffcile group (13.0%). On study day 16, 23.8% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this day, the stool consistency score for the BC30/C. difficile group (1.1 +/- 0.2) was significantly lower (p < 0.05) than for the vehicle/C. difficile cohort (1.9 +/- 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema, leukocyte influx) that was present following C. difficile infection. Colonic MIP-2 chemokine contents (pg/2 cm colon) were: 10.2 +/- 0.5 (vehicle/no C. difficile), 24.6 +/- 9.5 (vehicle/C. difficile) and 16.3 +/- 4.3 (BC30/C. difficle).Conclusion: The probiotic BC30 improved some parameters of C. difficile-induced colitis in mice. BC30 prolonged the survival of C. diffiicle infected mice. Particularly, this probiotic improved the stool consistency of mice, in this infectious colitis model.